MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Omnicell Inc

Fechado

SetorSaúde

38.17 1.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

37.6

Máximo

39.01

Indicadores-chave

By Trading Economics

Rendimento

-7.5M

-2M

Vendas

3.4M

314M

P/E

Médio do Setor

875.25

63.808

Margem de lucro

-0.645

Funcionários

3,580

EBITDA

-9.8M

21M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+53.59% upside

Dividendos

By Dow Jones

Próximos Ganhos

28 de abr. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-646M

1.6B

Abertura anterior

36.36

Fecho anterior

38.17

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Omnicell Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de abr. de 2026, 20:26 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 de abr. de 2026, 18:15 UTC

Notícias Principais

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 de abr. de 2026, 16:49 UTC

Notícias Principais

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 de abr. de 2026, 16:49 UTC

Notícias Principais

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 de abr. de 2026, 22:58 UTC

Ganhos

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 de abr. de 2026, 21:32 UTC

Conversa de Mercado

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 de abr. de 2026, 21:22 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de abr. de 2026, 21:22 UTC

Conversa de Mercado

Moody's Downgrades Belgium to A1 -- Market Talk

17 de abr. de 2026, 20:52 UTC

Ganhos

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

17 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de abr. de 2026, 20:29 UTC

Ganhos

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 de abr. de 2026, 19:34 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Global Equities Roundup: Market Talk

17 de abr. de 2026, 19:34 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 de abr. de 2026, 19:31 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 de abr. de 2026, 19:26 UTC

Conversa de Mercado

U.S. Natural Gas Futures Edge Up -- Market Talk

17 de abr. de 2026, 19:21 UTC

Conversa de Mercado

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 de abr. de 2026, 19:07 UTC

Conversa de Mercado

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 de abr. de 2026, 18:57 UTC

Notícias Principais

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 de abr. de 2026, 18:53 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 de abr. de 2026, 18:53 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB 2026 Rev Guidance Unchanged

17 de abr. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 de abr. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 de abr. de 2026, 18:14 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 de abr. de 2026, 18:00 UTC

Notícias Principais

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 de abr. de 2026, 18:00 UTC

Notícias Principais

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 de abr. de 2026, 17:31 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 de abr. de 2026, 17:26 UTC

Conversa de Mercado
Ganhos

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparação entre Pares

Variação de preço

Omnicell Inc Previsão

Preço-alvo

By TipRanks

53.59% parte superior

Previsão para 12 meses

Média 57.75 USD  53.59%

Máximo 70 USD

Mínimo 49 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Omnicell Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

5

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

24.23 / 30.44Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat